Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05839-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Jen-Pei Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou Dist, Taipei, 112201, Taiwan. Hauptthemen laut MEDLINE: Bendamustine Hydrochloride, Cytomegalovirus Infections, Lymphoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan, Taiwan Clinical Oncology Research Foundation, Yen Tjing Ling Medical Foundation.
Abstract (Originalsprache)
Bendamustine is used to treat lymphoma with excellent efficacy but is known for its immunosuppressive effect. Cytomegalovirus (CMV) reactivation after bendamustine use has been reported. We aim to address the impact of CMV infection in lymphoma patients treated with bendamustine-containing regimens. We retrospectively analyzed lymphoma patients at Taipei Veterans General Hospital in Taiwan between September 1, 2010, and April 30, 2022. Clinically significant CMV infection (CS-CMVi) was defined as the first CMV reactivation after bendamustine use necessitating CMV therapy. Patients' baseline characteristics and laboratory data were recorded. The primary endpoint of the study was CS-CMVi. A time-dependent covariate Cox regression model was used to estimate the risk factors of CS-CMVi and mortality. A total of 211 lymphoma patients treated with bendamustine were enrolled. Twenty-seven (12.8%) had CS-CMVi. The cumulative incidence was 10.1 per 100 person-years during the three-year follow-up period. In the multivariate analysis, lines of therapy before bendamustine ≥ 1 (95% CI 1.10-24.76), serum albumin < 3.5 g/dL (95% CI 2.63-52.93), and liver disease (95% CI 1.51-28.61) were risk factors for CS-CMVi. In conclusion, CS-CMVi (95% confidence interval [CI] 1.23-10.73) was one of the major independent risk factors of mortality. Lines of therapy before bendamustine ≥ 1, hypoalbuminemia, and liver disease were risk factors for CS-CMVi in lymphoma patients treated with bendamustine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou Dist, Taipei, 112201, Taiwan.
- Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Nursing, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou Dist, Taipei, 112201, Taiwan.
- Institute of Emergency and Critical Care Medicine, National Yang-Ming Chiao Tung University, No. 155, Section 2, Linong Street, Beitou District, Taipei, 112201, Taiwan.
- Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou Dist, Taipei, 112201, Taiwan.
Förderung
- Ministry of Science and Technology, Taiwan
- Taiwan Clinical Oncology Research Foundation
- Yen Tjing Ling Medical Foundation
- Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Ming University
- Taipei Veterans General Hospital
Zitieren
APA
Huang, J. P., Yeh, C. M., Gong, Y. W., Tsai, M. H., Lin, Y. T., Tsai, C. K., & Liu, C. J. (2024). Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine. Annals of Hematology. https://doi.org/10.1007/s00277-024-05839-0
Vancouver
Huang JP, Yeh CM, Gong YW, Tsai MH, Lin YT, Tsai CK, et al. Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine. Annals of Hematology. 2024. doi:10.1007/s00277-024-05839-0
BibTeX
@article{Huang2024,
author = {Huang, Jen-Pei and Yeh, Chiu-Mei and Gong, Ya-Wen and Tsai, Ming-Hsuan and Lin, Yi-Tsung and Tsai, Chun-Kuang and Liu, Chia-Jen},
title = {Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05839-0}
}
EUVIMED